WO2018183494A8 - Conjugués anticorps-médicament ciblant cd19 - Google Patents
Conjugués anticorps-médicament ciblant cd19 Download PDFInfo
- Publication number
- WO2018183494A8 WO2018183494A8 PCT/US2018/024840 US2018024840W WO2018183494A8 WO 2018183494 A8 WO2018183494 A8 WO 2018183494A8 US 2018024840 W US2018024840 W US 2018024840W WO 2018183494 A8 WO2018183494 A8 WO 2018183494A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug conjugates
- targeting antibody
- antibody
- targeting
- directed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des conjugués anticorps-médicament anti-CD19 et leur utilisation pour le traitement de malignités de lymphocytes B.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480217P | 2017-03-31 | 2017-03-31 | |
| US62/480,217 | 2017-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2018183494A1 WO2018183494A1 (fr) | 2018-10-04 |
| WO2018183494A8 true WO2018183494A8 (fr) | 2018-12-27 |
Family
ID=62025968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/024840 Ceased WO2018183494A1 (fr) | 2017-03-31 | 2018-03-28 | Conjugués anticorps-médicament ciblant cd19 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018183494A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022017595A2 (pt) * | 2020-03-03 | 2022-10-18 | Systimmune Inc | Anticorpos anti-cd19 e métodos de uso e fabricação dos mesmos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58620B1 (sr) | 2011-02-15 | 2019-05-31 | Immunogen Inc | Metodi pripremanja konjugata |
| EP2524929A1 (fr) * | 2011-05-17 | 2012-11-21 | Sanofi | Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B |
| BR112016026730A2 (pt) * | 2014-05-20 | 2017-12-12 | Immunogen Inc | métodos de caracterização e tratamento de leucemia mieloide aguda |
| PE20170775A1 (es) | 2014-09-03 | 2017-07-04 | Immunogen Inc | Derivados de benzodiazepina citotoxicos |
| CA2957964A1 (fr) * | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Conjugues comprenant des agents de liaison cellulaire et des agents cytotoxiques |
| JP6843080B2 (ja) | 2015-06-29 | 2021-03-17 | イミュノジェン・インコーポレーテッド | システイン改変抗体の複合体 |
-
2018
- 2018-03-28 WO PCT/US2018/024840 patent/WO2018183494A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018183494A1 (fr) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018112365A3 (fr) | Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii | |
| WO2016094837A3 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| IL277854A (en) | Conjugates of antibody and drug and their use for cancer treatment | |
| EP3735976A3 (fr) | Utilisation thérapeutique de mitochondries et d'agents mitochondriaux combinés | |
| WO2017201132A3 (fr) | Pyrrolobenzodiazépines et leurs conjugués | |
| WO2016134335A3 (fr) | Polypeptides pvrig et méthodes de traitement | |
| MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| MX2022002699A (es) | Lurbinectedina en el tratamiento del mesotelioma maligno. | |
| MX2020001632A (es) | Composiciones que comprenden cepas bacterianas. | |
| IL279609A (en) | Bifunctional compounds for cancer treatment | |
| ZA201907487B (en) | Compositions and treatment procedures for the treatment of pathogenic infections | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| WO2018237010A3 (fr) | Compositions vaccinales contre streptococcus et leurs méthodes d'utilisation | |
| WO2018183494A8 (fr) | Conjugués anticorps-médicament ciblant cd19 | |
| SG11202000612TA (en) | Methods and compositions for the treatment of melanoma | |
| MY182818A (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions | |
| SG11202000724XA (en) | Methods and compositions for the treatment of cancer | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| WO2019028012A3 (fr) | Procédés d'utilisation de pembrolizumab et de trébananib | |
| HK40093210A (en) | Methods and compositions for the treatment of cancer | |
| HK40059436A (en) | Herboxidiene antibody-drug conjugates and methods of use | |
| EP3876919A4 (fr) | Compositions pour le traitement du cancer et d'autres pathologies | |
| HK40029034A (en) | Methods and compositions for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18718987 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18718987 Country of ref document: EP Kind code of ref document: A1 |